Infeccion intraabdominal y nuevas quinolonas

Medicina

Volumn 59, Issue SUPPL. 1, 1999, Pages 47-54

  Gnocchi, Cesar A ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Intra abdominal infection; Peritonitis; Trovafloxacin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAFFEINE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINAFLOXACIN; GENTAMICIN; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; PEFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULTAMICILLIN; THEOPHYLLINE; TROVAFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES; CLINICAL TRIAL; DRUG FORMULATION; DRUG PENETRATION; DRUG TOLERABILITY; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONITIS; ANIMAL; CLASSIFICATION; HOSPITALIZATION; PROGNOSIS; RAT; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; PERITONITIS; PROGNOSIS; RATS; SEVERITY OF ILLNESS INDEX;

EID: 0042705193     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Condon RE, Wittmann DH. Intraabdominal infections: In: Gorbach SL, Bartlett JG, Blacklow NR (eds): Infectious Diseases, second edition. Philadelphia, W.B. Saunders Company 1998; 793-800.
2. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996; 224: 10-18.
3. Schein M. Management of severe intra-abdominal infection. Surg Annu 1992; 24: 47-68.
4. Butler JA, Huang J, Wilson SE. Repeated laparotomy for postoperative intra-abdominal sepsis. Arch Surg 1987; 12: 702-6.
5. Johnson CC, Baldesarre J, Levison ME. Peritonitis: Update on pathophysiology, clinical manifestations and management. Clin Infect Dis 1997; 24:1035-47.
6. Rangel-Frausto MS, Pittet D, Costigan M. The natural history of systemic inflammatory response syndrome (SIRS). JAMA 1995; 273: 117-23.
7. Wilson SE. A critical analysis of recent innovations in the treatment of intra-abdominal infection. Surg Gynecol Obstet 1993; 177: 11-17.
8. Saadia R, Lipman J. Antibiotics and the gut. Eur J Surg 1996; 576: 9-41.
9. Reemst PHM, Goor HV, Goris JA. SIRS. MODS and tertiary peritonitis. Eur J Surg 1996; 576: 47-9.
10. Tzianabos AO, Onderdonk AB, Rosner B. Structural features of polysaccharides that induce intraabdominal abscesses. Science 1993; 262: 416-20.
11. Tzianabos AO, Pantosti A, Baumenn H, Brisson JR, Jennings HJ, Kasper DL. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest 1995; 96: 727-2730.
12. Condon RE. Microbiology of intra-abdominal infection and contamination. Eur J Surg 1996; 576: 9-12.
13. Hopkins JA, Lee JCH, Wilson SE. Susceptibility of intra-abdominal isolates at operation: A predictor of postoperative infection. Am Surg 1993; 59:791-6.
14. Bartlett JG. Intra-abdominal sepsis. Med Clin NA 1995; 79: 599-617.
15. Wittmann DH, Bergstein JM, Frantzides C. Calculated empiric antimicrobial therapy for mixed surgical infections. Infection 1991; 19: S345-S350.
16. Weinstein WM, Onderdonk AB, Bartlett JG, Gorbach SL. Experimental intra-abdominal in rats: development of an experimental model. Infect Immun 1974; 10: 1250-1255.
17. Onderdonk AB, Bartlett JG, Louie T, Sullivan-Seigler N, Gorbach SL. Microbial sinergy in experimental intraabdominal abscess. Infect Immun 1976; 13: 22-28.
18. Rotstein OD, Pruett TL, Simmons RL. Mechanisms of microbial synergy in polimicrobial surgical infections. Rev Infect Dis 1985; 7: 151-170.
19. Nichols RL, Smith JW, Balthazar ER. Peritonitis and intra-abdominal abscess: An experimental model for the evaluation of human disease. J Surg Res 1978; 25: 129-135.
20. Nichols RL, Smith JW, Fossedal EN, Condon RE. Efficacy of parenteral antibiotics in the treatment of experimentally induced intrabdominal sepsis. Rev Infect Dis 1979; 1: 302-306.
21. Montravers P, Andremont A, Massias L, Carbon C. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis 1994; 169: 821-830.
22. Barie PS. Emerging problems in Gram positive infections in the postoperative patient. Surg Gynecol Obstet 1993; 177; 55-64.
23. Barie PS, Christou NV, Dellinger EP. Pathogenicity of the enterococcus in surgical infections. Ann Surg 1989; 212: 155-59.
24. de Vera ME, Simmons RL. Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996; 131: 338-42.
25. Davis JM, Huycke MM, Wells CL. Surgical Infection Society position on vancomycin resistant enterococcus. Arch Surg 1996; 131:1061-8.
26. Rotsein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patiens in the intensive care unit. Can J Surg 1986; 29: 247-50.
27. Sawyer RG, Rosenlof LK, Adams RB, May AK, Spengler MD, Pruett TL. Peritonitis in the 1990s: changing pathogens and changing strategies in the critically ill. Am Surgeon 1992; 58: 82-7.
28. Henderson VJ, Hirvela ER. Emerging and reemerging microbial threats. Arch Surg 1996; 131: 300-37.
29. Sawyer MD, Dunn DL. Antimicrobial Theraphy of intra-abdominal sepsis. Infect Dis Clin North Am 1992; 6:545-570.
30. Parrillo JE. Pathogenic mechanisms of septic shock. N Engl J Med 1993; 328:1471-7.
31. Patel RT, Deen KI, Youngs J. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81: 1306-8.
32. Holzheimer RG, Schein M, Wittmann DH. Inflammatory Mediators in Plasma and Peritoneal Exudate of Patiens Undergoing Staged Abdominal Repair (STAR) for Severe Peritonitis. Arch Surg 1995; 130: 1314-20.
33. Schein M, Wittmann DH, Holzheimer R, Condon RE. Hypothesis: Compartmentalizaction of cytokines in intraabdominal infection. Surgery 1996; 119: 694-700.
34. Bohnen JMA, Solomkins JS, Dellinger EP. Guidelines for clinical care: Antiinfective agents for intra-abdominal infection: A Surgical Infection Society Policy Statement. Arch Surg 1992; 127: 83-9.
35. Nichols RE. Surgical infections: Prevention and treatment-1965 to 1995. Am J Surg 1996; 172: 68-74.
36. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of antimicrobial therapy. Clin Infect Dis 1996;23:486-94.
37. Nathens AB, Rotstein OD. Antimicrobial therapy for intra-abdominal infection. Am J Surg 1996; 172 : 1S-6S.
38. Nathens AB, Rotstein OD. Therapeutic options in peritonitis. Surg Clin NA 1994; 74: 677-91.
39. Mosdell DM, Morris DM, Voltura A, Pitcher DE, Twiest MW, Milne RL, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543-9.
40. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 1994; 81: 989-91
41. Schein M. Planned reoperations and open management in critical intra-abdominal infections: prospective experience in 52 cases. World J Surg 1991; 15: 537-45.
42. Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, et al. Prognosis in intra-abdominal infections. Arch Surg 1996; 131: 641-5.
43. Smith JA, Skidmore AG, Forward AD, Clarke AM, Sutherland E. Prospective, randomized, double-blind comparison of metronidazol and tobramycin with clindamycin and tobramycin in the treatment of intra-abdominal sepsis. Ann Surg 1980; 192: 213-20.
44. Harding GKM, Nicolle LE, Haase DA. Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections. Rev Infect Dis 1984; 6 :S283-S292.
45. Gorbach SL. Intra-abdominal infections: state of the art clinical article. Clin Infect Dis 1993; 17: 961-7.
46. Luke M, Iversen J, Sondergaard J. Ceftriaxone/ metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991; 157: 397-402.
47. Study Group of intraabdominal infections: A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intra-abdominal infections: A preliminary report. Rev Infect Dis 1986; 8: S583-S587.
48. Yellin AE, Heseltine PNR, Berne TV, Appleman MD, Gill MA. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985; 161: 303-307.
49. Hackford AW, Tally FP, Reinhold RB, Barza M, Gorbach SL. Prospective study comparing imipenem-cilastin wiyh clindamycin and gentamicin for the treatment of surgical infections. Arch Surg 1988; 123: 322-326.
50. Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E et al. Piperacillin/tazobactam versus imipenem/clastin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176: 255-261.
51. Condon RE, Walker AP, Sirinek KR. Meropenem versus tobramycin plus clindamycin for treatment of intra-abdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21: 544-550.
52. Polk HC, Fink MP, Laverdiere M, Wilson SE, Garber GE, Barie PS et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Amn Surg 1993; 59: 598-605.
53. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982; 195:19-24.
54. Stone HH, Bourneuf AA, Stinson LD. Reliability of criteria for predicting persistent or recurrent sepsis. Arch Surg 1985; 120: 17-20.
55. Wittmann DH, Schein M. Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 1996; 172: 26S-32S.
56. Pollok AV. At what point is infection cured but inflammation persists? Eur J Surg 1996; 576 : 13-5.
57. Lahnborg G, Hedstron KG, Nord CE. Efficacy of different antibiotics in the treatment of experimentally induced intra-abdominal sepsis. J Antimicrob Chemother 1982; 10: 497-504.
58. Smith JA. Treatment of intra-abdominal infections with quinolones. Eur J Clin Microbiol Infect Dis 1991 ; 10: 330-3.
59. Swedisch Study Group (Kager L, Brismar B, Edlund C). A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. J Antimicrob Chemother 1990; 26 (suppl B): 173-80.
60. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB et al. Results of randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996; 223: 03-315.
61. Neu HC. The quinolones. Infect Dis Clin NA 1989; 3: 625-39.
62. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378-81.
63. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In-vitro activity of clinafloxacin, trovafloxacin and ciprofloxacin. J Antimicrobial Chemother 1997; 40: 205-11.
64. Gooding BB, Jones RN. In-vitro antimicrobial activity of CP 99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37: 349-53.
65. Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP 99, 219, a new naphthyridone antimicrobial agent a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869-876.
66. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In-vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996; 40: 2232-5
67. Citron DM, Appleman MD. Comparative in-vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 1997; 41: 2312-16.
68. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996; 23 S2-S8.
69. Nord CE. In-vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis 1996; 23 (suppl 1): S15-S18.
70. Guay DRP. The role of the fluoroquinolones. Pharmacotherapy1992; 12: 71S-85S.
71. Batty KT, Davis TM, llett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on the theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39: 305-11.
72. Vincent J, Teng R, Dogolo LC, Willivize SA, Friedman HL. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997; 39: en prensa.
73. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996; 23: S19-S24.
74. Goldstein EJC. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis 1996; 23: S25-S30.